Faculty Scholarship

2003

Activation Of Jnk By Vanadate Induces A FasAssociated Death Domain (Fadd)-Dependent
Death Of Cerebellar Granule Progenitors In Vitro
Jia Luo
Yanbo Sun
Hong Lin
Yong Qian
Zheng Li
See next page for additional authors

Follow this and additional works at: https://researchrepository.wvu.edu/faculty_publications
Digital Commons Citation
Luo, Jia; Sun, Yanbo; Lin, Hong; Qian, Yong; Li, Zheng; Leonard, Stephen S.; Huang, Chuanshu; and Shi, Xianglin, "Activation Of Jnk
By Vanadate Induces A Fas-Associated Death Domain (Fadd)-Dependent Death Of Cerebellar Granule Progenitors In Vitro" (2003).
Faculty Scholarship. 458.
https://researchrepository.wvu.edu/faculty_publications/458

This Article is brought to you for free and open access by The Research Repository @ WVU. It has been accepted for inclusion in Faculty Scholarship
by an authorized administrator of The Research Repository @ WVU. For more information, please contact ian.harmon@mail.wvu.edu.

Authors

Jia Luo, Yanbo Sun, Hong Lin, Yong Qian, Zheng Li, Stephen S. Leonard, Chuanshu Huang, and Xianglin Shi

This article is available at The Research Repository @ WVU: https://researchrepository.wvu.edu/faculty_publications/458

THE JOURNAL

OF

BIOLOGICAL CHEMISTRY

Vol. 278, No. 7, Issue of February 14, pp. 4542–4551, 2003
Printed in U.S.A.

Activation of JNK by Vanadate Induces a Fas-associated Death
Domain (FADD)-dependent Death of Cerebellar Granule
Progenitors in Vitro*
Received for publication, August 13, 2002, and in revised form, November 21, 2002
Published, JBC Papers in Press, November 25, 2002, DOI 10.1074/jbc.M208295200

Jia Luo‡§, Yanbo Sun‡, Hong Lin‡, Yong Qian¶, Zheng Li‡, Stephen S. Leonard¶,
Chuanshu Huang储, and Xianglin Shi¶
From the ‡Department of Microbiology, Immunology and Cell Biology, West Virginia University School of Medicine,
Robert C. Byrd Health Science Center, Morgantown, West Virginia 26506, ¶Pathology and Physiology Research Branch,
NIOSH, National Institutes of Health, Morgantown, West Virginia 26505, and 储New York University Medical Center,
Nelson Institute of Environmental Medicine, Tuxedo, New York 10987

Apoptosis, or programmed cell death, plays an important
role in shaping the developing nervous system, removing unwanted neurons, and establishing correct synaptic connections
with the targets they innervate (1– 4). In the adult, inappropriate apoptosis in the central nervous system may contribute to
a number of neurodegenerative diseases including Alzheimer’s
disease, Parkinson’s disease, and stroke (5– 8). Understanding
the mechanisms that govern neuronal apoptosis could lead to
more effective therapies for these disorders.
Mitogen-activated protein kinases (MAPKs)1 play an instru-

mental role in the transmission of signals from cell surface
receptors and environmental cues to the transcriptional machinery. Three major MAPKs have been identified: the extracellular signal-regulated kinases (ERKs), the c-Jun NH2-terminal protein kinases (JNKs), and the p38 mitogen-activated
protein kinase (p38 MAPK). ERKs are mainly activated by
growth factors and are involved in the regulation of cell proliferation (9, 10). Unlike ERKs, JNKs and p38 MAPK are most
potently activated by environmental stresses. JNKs are identified through their ability to phosphorylate the N-terminal
stimulatory sites of c-Jun (11). Along with JNKs, p38 MAPKs
are implicated in the regulation of cell death. JNKs and p38
MAPK may regulate apoptosis positively or negatively depending on cell type (12–15). However, the mechanisms by which
JNKs and p38 MAPKs regulate neuronal apoptosis are not
clear. Conflicting results have been published regarding the
role of JNKs and p38 MAPK signaling in the control of neuronal apoptosis (16 –26).
The trace metal vanadium is widely distributed in the environment (27, 28). It exists in oxidation states ranging from ⫺1
to ⫹5. Among these oxidation states the pentavalent state is
the most stable form. In mammalian systems vanadium, the
vanadate, is the most toxic form. Occupational exposure to
vanadium is common in oil-fired electrical generating plants
and petrochemical, steel, and mining industries (28, 29). Vanadate-containing compounds exert toxic effects on a wide variety of biological systems (30 –34). Developmental exposure to
vanadium is teratogenic and results in profound defects in the
central nervous system (35– 40). The objective of this study was
to determine the mechanisms of vanadate-induced damages to
the developing central nervous system and define the role of
MAPKs in the regulation of neuronal apoptosis.
The developing cerebellum is one of the regions that is most
susceptible to environmental insults, and vanadium compounds are deposited in the human cerebellum (41). Cerebellum granule neurons, the major cerebellar neuronal population, are generated in the proliferative external germinal layer
of the cerebellum during the first 2–3 postnatal weeks in the
rat (42, 43). During the early postnatal period, cells in the
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Apoptosis is a highly regulated process that plays a
critical role in neuronal development as well as the homeostasis of the adult nervous system. Vanadate, an
environmental toxicant, causes developmental defects
in the central nervous system. Here, we demonstrated
that vanadate induced apoptosis in cultured cerebellar
granule progenitors (CGPs). Treatment of cultured
CGPs with vanadate activated ERKs and JNKs but not
p38 MAPK and also induced c-Jun phosphorylation. In
addition, vanadate induced FasL production, Fas
(CD95) aggregation, and its association with the Fasassociated death domain (FADD), as well as the activation of caspase-8. Furthermore, vanadate generated reactive oxygen species (ROS) in CGPs; however, ROS was
not involved in vanadate-mediated MAPK activation.
Vanadate-induced FasL expression was ROS-dependent
but JNK-independent. In contrast, vanadate-elicited Fas
aggregation and Fas-FADD association, as well as
caspase-8 activation, were dependent on JNK activation
but were minimally regulated by ROS generation. The
hydrogen peroxide scavenger, catalase, blocked vanadate-induced FasL expression and partially mitigated
vanadate-induced cell death. On the other hand, dominant negative FADD and caspase-8 inhibitor completely
eliminated vanadate-induced apoptosis. Thus, JNK signaling plays a major role in vanadate-mediated activation of the Fas-FADD-caspase-8 pathway that accounts
for vanadate-induced apoptosis of CGPs.
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external germinal layer undergo extensive proliferation to generate a large pool of cerebellar granule progenitors (CGPs). The
developing CGPs then exit the cell cycle and migrate inward
past Purkinje cell bodies to their final destination in the internal granule layer, where they differentiate into cerebellar granule neurons (42, 43). The CGPs isolated from 3–5-day (a time
when CGPs are being generated and proliferating in vivo)-old
rat pups retain their proliferative capability in vitro and are
able to differentiate into neurons (44 – 47). This in vitro system
offers an excellent model for study of neuronal development.
Here, we demonstrate that vanadate induces apoptosis of
CGPs. JNK signaling and the death receptor Fas (CD95) play a
central role in vanadate-mediated neuronal death.

with morphometric indices of apoptosis or the terminal deoxynucleotidyl
transferase-mediated dUTP-biotin nick end-labeling assay (47, 51).
Nuclear Morphology—Cell death was also determined by counting
the amount of cells containing condensed or fragmented nuclei in a
blinded manner (52). Briefly, cells were fixed with 2.0% paraformaldehyde in phosphate-buffered saline (PBS) for 30 min at room temperature. Cell membranes were permeabilized by treating the cells with
0.10% Triton X-100 in PBS for 15 min and then stained with a DNA dye,
TOTO-3 iodide (3.0 g/ml; Molecular Probes Inc., Eugene, OR), for 30
min at 37 °C to visualize nuclear morphology. After being washed with
PBS, the cells were examined under a Zeiss LSM 510 confocal microscope. Apoptotic neurons were determined by counting the cells containing condensed or fragmented nuclei in 4 –5 fields/well. At least 200
cells were counted.

EXPERIMENTAL PROCEDURES

Caspase activity was determined using commercial fluorometric protease assay kits. Kits for assaying caspase-3 and caspase-8 activation
were obtained from Santa Cruz Biotechnology and the caspase-9 activity kit from R&D Systems. The activation of caspases was determined
for their protease activity by the addition of a caspase-specific substrate
peptide that is conjugated to the fluorescent reporter molecule 7-amino4-trifluoromethyl coumarin. The cleavage of the substrate peptide by
specific caspase releases the fluorochrome that emits fluorescence at
505 nm when excited by light with a 400-nm wavelength. The level of
caspase enzymatic activity is directly proportional to the fluorescence
signal detected with a fluorometer.

Reagents
Sodium metavanadate (vanadium (V), NaVO3, or vanadate, catalog
no. 2839-1) was purchased from Sigma. Caspase-3 inhibitor Ac-DMQDCHO, caspase-8 inhibitor Z-IETD-FMK, and caspase-9 inhibitor
ZlEHD-FMK were obtained from Calbiochem. Anti-Fas antibodies,
SM1/23 and FL-335, were purchased from Alexis Biochemicals (San
Diego, CA) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively. Fas-Fc fusion protein was purchased from R&D Systems
(Minneapolis, MN). Anti-Fas ligand (FasL) (N-20) and anti-FADD antibodies (H-181) were obtained from Santa Cruz Biotechnology. Human
recombinant FasL was obtained from Upstate Biotechnology Inc. (Lake
Placid, NY). Deferoxamine, superoxide dismutases, and sodium formate
were purchased from Sigma. Catalase was obtained from Roche Molecular Biochemicals. The inhibitors for protein tyrosine phosphatase (␣bromo-4-hydroxyacetophenone), p38 MAPK (SB202190), and MEK1
(PD98059) were purchased from Calbiochem, and a selective JNK inhibitor (D-JNKI1) was purchased from Alexis Biochemicals.

Culture of CGPs
The CGPs were isolated from the cerebella of 3-day-old SpragueDawley rats (Hilltop Laboratory Inc., Scottsdale, PA) using a previously
described procedure (47, 48). The purity of CGPs generated using this
procedure is greater than 95.0%. Isolated CGPs were plated into polyD-lysine (50.0 g, Sigma)-coated culture wells or dishes at a density of
3.2 ⫻ 104/cm2. The cultures were grown in Eagle’s minimal essential
medium containing the following supplements: 10.0% fetal bovine serum, 25.0 mM KCl, 1.0 mM glutamine, 33.0 mM glucose, and penicillin
(100 units/ml)/streptomycin (100.0 g/ml). Cells were incubated at
37 °C in a humidified environment containing 5.0% CO2.

Cell Growth and Proliferation
The number of viable cells in culture was determined by the MTT
assay (catalog no. 1 465 007, Roche Molecular Biochemicals). Briefly,
the CGPs were plated into 96-well microtiter plates at a density of 3.2 ⫻
104/cm2. 10 l of MTT labeling reagent was added to each well, and
plates were incubated at 37 °C for 4 h. After MTT incubation the
cultures were solubilized, and spectrophotometric absorbance of the
samples was detected by a microtiter plate reader. The wavelength to
measure the absorbance of formazan product was 570 nm with a reference wavelength of 750 nm. We have demonstrated that the MTT assay
is an accurate method to determine the number of viable cells (47, 49).
Cell proliferation was determined by pulse labeling of 5-bromo-2⬘-deoxyuridine (BrdUrd) (47, 50). Briefly, cells were plated into wells of
removable chamber slides at the density of 3.2 ⫻ 104/cm2 and exposed
to 20.0 M BrdUrd (Sigma) for 12 h. BrdUrd positive cells were visualized immunohistochemically using an anti-BrdUrd monoclonal antibody (Sigma). The numbers of BrdUrd positive and negative cells
within an area of 0.5 ⫻ 0.5 mm were counted. Five fields were chosen at
random in each slide and counted. A BrdUrd labeling index (the number of labeled cells divided by the total number of cells counted) was
calculated.

Apoptosis Assays
Cellular DNA Fragmentation ELISA—This assay is based on quantification of accumulation of DNA fragments in the cytoplasm of apoptotic cells. Accumulation of cytosolic histone-bound DNA fragments was
quantified using a commercial ELISA kit (catalog no. 1 544 675, Roche
Molecular Biochemicals). The measurement of apoptosis, which was
demonstrated previously, was sensitive, and the outcome was consistent

Caspase Activity

Immunoblot and Immunoprecipitation Analysis
Cell lysates (40 –100 g of protein) were resolved by SDS-PAGE on
8 –12% polyacrylamide gels, and separated proteins were transferred to
nitrocellulose membranes. After blocking with 5.0% nonfat milk in
TPBS (0.010 M PBS, pH 7.4, and 0.10% Tween 20) at room temperature
for 1 h, the membranes were probed with various antibodies directed
against activated MAPKs or phosphorylated tyrosine. These antibodies
include anti-phospho-c-Jun, anti-phospho-p38 MAPK, anti-phospho
ERK, anti-JNK1, anti-c-Jun, anti-p38, and anti-ERK, which were obtained from Santa Cruz Biotechnology. Anti-phospho-JNK antibody
was purchased from Promega (Madison, WI) and anti-phosphotyrosine
antibody from Cell Signaling Technology, Inc. (Beverly, MA). The antibody-antigen complexes were visualized by enhanced chemiluminescence (Amersham Biosciences). The blots were stripped and reprobed with
an anti-␤-actin antibody (Santa Cruz Biotechnology). The variation in
loading was normalized against the amount of actin expression in each
lane. Each experiment was repeated three to four times for each primary
antibody. The relative amount of specific protein imaged on the films was
quantified using a Sigma Gel program (Jandel, San Rafael, CA). Fas was
immunoprecipitated from cell lysates (200.0 g of total protein) by an
anti-Fas antibody (Santa Cruz Biotechnology) using a previously described method (53). Immunoprecipitates were electrophoretically separated and transferred to nitrocellulose membranes. FADD associated
with Fas was examined by immunoblotting using an anti-FADD antibody.

Fas Aggregation
Fas aggregation was determined using a previously described
method (54, 55). Basically, when antibody is limiting (0.1– 0.5 g/ml),
more molecules of the Fas will be immunoprecipitated if aggregation
occurs after vanadate treatment. In contrast, when antibody is not
limiting (5–10 g/ml), equal amounts of Fas should be immunoprecipitated. Briefly, cells were treated with vanadate (25.0 M, 6 h), resuspended in 500 l of PBS, and then incubated with 2.0 mM cross-linker
3,3⬘-dithiobis-[sulfosuccinimidyl propionate] (Sigma) for 15 min on ice.
The reaction was quenched with 10.0 mM ammonium acetate for 10 min
and the cells were washed with PBS and then lysed. Fas was immunoprecipitated using either limiting or excess amounts of anti-Fas antibody and detected by immunoblot.

Cell Transfection
The pcDNA3.0/DN-FADD vector (kindly provided by Dr. V. M. Dixit,
Genetech, San Francisco, CA) carries a truncated FADD cDNA lacking
the death effector domain (DED) region (56, 57). pEGFP-C3 encoding
the green fluorescent protein was obtained from Clontech Laboratories
(Palo Alto, CA). The cells were transfected with pEGFP-C3 (0.30 g)
and DN-FADD (1.0 g) or an empty pcDNA3.0 vector (1.0 g) using
LipofectAMINE 2000 reagent (Invitrogen) according to the manufacturer’s instructions. One day after the transfection the CGPs were
treated with vanadate (25.0 M) for 24 h. Nuclei were stained with
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FIG. 1. Effects of vanadate on the survival and proliferation of CGPs. The CGPs were plated at a density of 3.2 ⫻ 104/cm2. At 24 h after
plating cells were treated with vanadate. A, effect of vanadate on cell number. Cells were exposed to vanadate (0 –100.0 M) for 48 h, and the
number of viable cells was determined with the MTT assay. B, vanadate-induced apoptosis. Cells were exposed to vanadate (0 –100.0 M) for 24 h,
and apoptosis was determined by a DNA fragmentation ELISA. C, assaying apoptosis by nuclear morphology. Cells were exposed to vanadate (25.0
M) for 24 h and stained with the DNA dye TOTO-3 iodide (3.0 g) for 30 min. Cells were examined under a confocal microscope. D, relative
apoptosis shown in C was quantified by determining the nuclei fragmentation and condensation as described under “Experimental Procedures.”
E, time course of vanadate-mediated apoptosis. Cells were exposed to vanadate (25.0 M) for various durations (6 –72 h), and apoptosis was
determined with a DNA fragmentation ELISA. F, DNA synthesis. Cells were treated with vanadate (25.0 M) for 24 h. Subsequently, cells were
exposed to BrdUrd (20.0 M) for 12 h. The incorporation of BrdUrd was determined immunohistochemically as described under “Experimental
Procedures.” Each data point (bars; ⫾ S.E.) is the mean of 3– 4 independent trials. *, denotes a statistically significant difference between control
and treated groups (p ⬍ 0.05).
TOTO-3 iodide, and apoptotic neurons in total transfected (green fluorescent protein-positive) cells were determined as described above.

Electron Spin Resonance (ESR) Measurements
The ESR spin trapping technique with 5,5-dimethyl-1-pyrroline Noxide (DMPO) as the spin trap was used to detect free radical generation. This technique involves the formation of an adduct of a short-lived
radical with a diamagnetic compound (spin trap) to generate a relatively long-lived free radical product (spin adduct), which can be studied
by conventional ESR. The intensity of the spin adduct signal corresponds to the amount of short-lived radicals trapped, whereas the
hyperfine couplings of the spin adduct are characteristics of trapped
radicals. The spectra were recorded using a Varian E9 ESR spectrometer
and a flat cell assembly as described previously (58). Hyperfine couplings
were measured (to 0.1 G) directly from magnetic field separation using
potassium tetraperoxochromate (K3CrO8) and 1,1-diphenyl-2-picrylhydrazyl as reference standards. 500.0 l of cell suspension (1 ⫻ 106/0.5 ml)
was mixed with 500.0 l of PBS containing 100.0 mM DMPO and 1.0 mM
vanadate with/without ROS scavengers. The reaction mixture (500.0 l)
was transferred to a flat cell for ESR measurement.

Statistical Analysis
Treatment groups were compared using analysis of variance. In
cases where significant differences (p ⬍ 0.05) were detected, specific
post hoc comparisons between treatment groups were examined with
the Student-Newman-Keuls tests.

RESULTS

Vanadate-induced Apoptosis in Cultured CGPs—Vanadate
exposure reduced the number of viable cells in a concentrationdependent manner (Fig. 1A). Concomitantly, vanadate increased apoptotic death, which was determined by a cellular
DNA fragmentation ELISA in a dose-dependent manner (Fig.
1B). At a concentration of 25.0 M, vanadate treatment (24 h)
increased death rate by 3.4-fold. Vanadate-induced apoptosis
was verified with an analysis of nuclear morphology by TOTO-3 iodide staining; it showed a 3.1-fold increase in apoptotic
rate after vanadate treatment (Fig. 1, C and D). Time course
analysis revealed that maximal apoptosis occurred 24 – 48 h
after vanadate treatment (Fig. 1E). Because CGPs proliferate
in culture, we sought to determine whether vanadate affects
the proliferation of CGPs. As shown in Fig. 1F, vanadate (25.0
M) produced a small but statistically significant decrease
(⫺19%; p ⬍ 0.05) of BrdUrd positive cells. In contrast, at this
concentration vanadate decreased the number of CGPs by more
than 70%. When these facts are taken together, it can be
concluded that vanadate-induced depletion of cell number was
mainly caused by the cell death.
Vanadate-mediated MAPK Activation—Vanadate produced
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FIG. 2. Vanadate-mediated activation of MAPK and protein tyrosine phosphorylation. The CGPs were grown in a serum-free medium
for 24 h and treated with vanadate (25.0 M) for various lengths of time. The activation of MAPKs and protein tyrosine phosphorylation was
determined with immunoblotting using specific antibodies. After detection of phosphorylated forms of MAPKs, the blots were stripped and
reprobed with antibodies directed against nonphosphorylated kinases. A, JNK and c-Jun activation; B, ERK activation; C, protein tyrosine
phosphorylation; D, tyrosine phosphorylation on JNK1. Cells were exposed to vanadate with/without catalase for 6 h, and JNK1 was immunoprecipitated using a specific antibody. The immunoprecipitates were assayed for tyrosine phosphorylation (top panel) or JNK1 expression (bottom
panel). The experiments were replicated three times.

a sustained activation of JNK1 but did not affect JNK1 expression (Fig. 2A). The antibody applied reacts with both JNK1 and
JNK2 (Promega, catalog no. V7932), but only phosporylated
JNK1 was detected. The activation lasted for at least 12 h. As
a result of JNK activation, vanadate induced phosphorylation
of c-Jun, a main target of JNKs, in a pattern similar to that of
JNK1 (Fig. 2A). Vanadate had little effect on c-Jun expression.
Vanadate also produced a transient activation of ERK1/2 (Fig.
2B). The activation of ERK1/2 was evident 15 min after vanadate treatment, and the effect diminished after 2 h. Vanadate
had little effect on the expression of ERK1/2. We also examined
the effect of vanadate on p38 MAPK. Vanadate did not significantly alter either the expression or the activation of p38
MAPK in CGPs (data not shown). Vanadium compounds may
serve as protein tyrosine phosphatase (PTP) inhibitor and subsequently enhance protein tyrosine phosphorylation (59, 60).
We then examined the effect of vanadate on protein tyrosine
phosphorylation of total cellular extracts. As shown in Fig. 2, C
and D, vanadate treatment increased tyrosine phosphorylation
on a number of proteins including JNK1 as determined by
immunoprecipitation.
Vanadate-induced FasL Production, Fas-FADD Association,
Fas Aggregation, and Caspase Activation—Because vanadate
induced apoptotic death of CGPs (Fig. 1), we sought to determine the mechanisms of vanadate-induced damage. Death receptor Fas is an apoptotic sensor that transmits a death signal
(61, 62). The adapter molecule FADD couples with the death
receptor Fas to procaspase-8 (63). As shown in Fig. 3A, vanadate produced a concentration-dependent up-regulation in the
expression of FasL. Although vanadate did not alter the expression of Fas and FADD, it induced an association between
these proteins (Fig. 3B). Vanadate-induced activation of Fas
was further confirmed by the evidence showing an increase in

Fas aggregation (Fig. 3C). As shown in Fig. 3C, vanadate
induced a JNK-dependent Fas aggregation. Because caspases
play a critical role in the initiation of apoptosis, we sought to
determine whether vanadate activates caspases. As shown in
Fig. 4, vanadate treatment significantly (p ⬍ 0.05) activated
caspases-3 and -8, but had little effect on caspase-9 (Fig. 4).
Vanadate-induced ROS Generation—ROS is involved in apoptosis (64). Vanadate is able to generate a whole spectrum of
ROS, i.e. O2. , H2O2 and 䡠OH (65). To determine whether vanadate-induced apoptosis of CGPs is mediated by ROS, we first
examined the ROS generation in the vanadate-treated cells.
The ability of vanadate to generate 䡠OH radicals was examined
using an ERS spin trapping method with DMPO as the spin
trap. As shown in Fig. 5, vanadate treatment generated a
typical ESR spectrum of free radicals. The spectrum consists of
a 1:2:2:1 quartet with splittings of aH ⫽ aN ⫽ 14.9 G, where aN
and aH denote hyperfine splitting of the nitroxyl nitrogen and
␣– hydrogen, respectively. On the basis of these splittings and
the 1:2:2:1 line shape, this spectrum was assigned to the
DMPO/䡠OH adduct, which is evidence for 䡠OH radical generation. The addition of catalase, a specific H2O2 scavenger, completely eliminated the 䡠OH radical, indicating that H2O2 was
generated in vanadate-stimulated cells and was a precursor of
䡠OH generation. Sodium formate, a scavenger of 䡠OH radical,
and deferoxamine, a metal chelator, decreased the intensity of
the radical signal. In contrast, superoxide dismutase, an O2. scavenger the function of which is to convert O2. to H2O2, increased
the DMPO/䡠OH adduct signal. The results were similar in three
independent experiments. The finding indicated that vanadate
was able to generate a whole spectrum of ROS in CGPs.
Vanadate-induced FasL Production and Fas-FADD Association Involve Different Mechanisms—Catalase, a specific H2O2
scavenger, eliminated vanadate-induced ROS generation (Fig.
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FIG. 3. Effects of vanadate on FasL, Fas, and FADD. A, expression of FasL, Fas, and FADD. The CGPs were treated with vanadate (0 – 40.0
M) for 24 h, and total proteins were isolated. Equal amounts of proteins (60.0 g) were subjected to immunoblot analysis. After the detection of
FasL, Fas, and FADD, the blots were stripped and reprobed with an anti-actin antibody. B, vanadate-mediated association between Fas and FADD.
Cells were treated with vanadate (25.0 M) for 6 h, and proteins were isolated. Cell lysates were immunoprecipitated with an anti-Fas antibody
and probed with an anti-FADD antibody. C, vanadate-mediated Fas aggregation. Cells were treated with vanadate (25.0 M) for 6 h in the
presence/absence of D-JNKI1 or catalase. Cell lysates were treated with a cross-linking reagent and immunoprecipitated using an anti-Fas
antibody under antibody-limiting conditions (top panel) or antibody-excess conditions (bottom panel). Panels on the right were the microdensitometrical quantification of relative expression. Each data point (bars; ⫾ S.E.) is the mean of three independent trials. *, denotes a statistically
significant difference between control and treated groups (p ⬍ 0.05).

5); however, it did not affect vanadate-mediated JNK and ERK
activation (Figs. 2D and 6). D-JNKI1, a specific inhibitor for
JNK1/2 (66), and PD98059, an inhibitor for MEK1, completely
blocked vanadate-induced phosphorylation of c-Jun and
ERK1/2, respectively. Interestingly, although catalase did not
block vanadate-induced MAPK activation, it eliminated the
vanadate-mediated increase in FasL production (Fig. 7A). In
contrast, D-JNKI1 and other ROS scavengers/promoters did
not significantly alter FasL production (Fig. 7A). The levels of
FasL were also unaffected by PD98059 (data not shown). These
results indicated that the H2O2 was critical in vanadate-induced increase in FasL expression.
Because catalase blocked the vanadate-induced increase in

FasL expression, we examined the effect of catalase on Fas
aggregation and Fas-FADD association. As shown in Figs. 3C
and 7B, catalase produced a modest inhibition on vanadateinduced Fas aggregation and Fas-FADD association. Despite
its lack of effect on FasL production, D-JNKI1 dramatically
inhibited vanadate-induced Fas aggregation and Fas-FADD
association. The combination of catalase and D-JNKI1 treatment completely abolished vanadate-mediated Fas-FADD association (Fig. 7B). PD98059 did not affect the interaction
between Fas and FADD. Taken together, these observations
indicate that vanadate-induced FasL production is independent of MAPK activation but is dependent on H2O2 generation.
In contrast, JNK activation is not required for vanadate-in-
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vanadate-induced apoptosis, we determined whether blockage
of MAPK activation or H2O2 removal could protect CGPs from
vanadate-induced cell death. Removal of H2O2 by catalase produced a partial and statistically significant (p ⬍ 0.05) rescue
(Fig. 10). Inhibition of JNK activation exerted a more potent
protection against vanadate-induced damage. Furthermore, simultaneous treatment with catalase and D-JNKI1 completely
abolished vanadate-mediated cell death. Vanadate-triggered
cell death remained unaffected by both PD98059 and SB
292190 treatment.
Vanadate may serve as a PTP inhibitor. To determine
whether other inhibitors for PTP have the same effect as vanadate, we examined the effect of ␣-bromo-4-hydroxyacetophenone, a specific PTP inhibitor, on CGPs. The results indicated
that this inhibitor did not significantly induce apoptosis (data
not shown), suggesting that the effect of vanadate is not mediated by a general inhibition of tyrosine dephosphorylation.
DISCUSSION

FIG. 4. Effects of vanadate on caspase activity. The CGPs were
treated with vanadate (25.0 M) for 24 h. The activity of caspase-3, -8,
and -9 was determined as described under “Experimental Procedures.”
Each data point (bars; ⫾ S.E.) is the mean of four independent trials. *,
denotes a statistically significant difference between control and
treated groups (p ⬍ 0.05).

duced increase in FasL production but is essential for the
activation of Fas and subsequent Fas-FADD association.
Because vanadate-induced JNK activation triggered FasFADD association, we further examined whether the activation
of caspase-8 was mediated by JNKs. As shown in Fig. 7C,
D-JNKI1 abolished vanadate-induced caspase-8 activation. On
the other hand, catalase produced only a marginal inhibition on
vanadate-induced caspase-8 activation. PD98059 had no effect
on caspase-8 activation.
Vanadate-induced Apoptosis Is Mediated by FADDCaspase-8 Pathway—Because vanadate increased FasL expression (Fig. 3A), we sought to determine whether the apoptosis of CGPs is mediated by the FasL-Fas interaction. Two
Fas antagonists, SM1/23 and Fas-Fc, were introduced. These
antagonists effectively abolished FasL-Fas interaction (67, 68)
and eliminated recombinant FasL-induced apoptosis in CGPs
(data not shown). However, both antagonists produced only a
modest but statistically significant (p ⬍ 0.05) inhibition of
vanadate-induced apoptosis (Fig. 8). These results suggested
that although FasL induction was involved it was not the
primary mechanism for vanadate-induced apoptosis of CGPs.
The Fas-mediated apoptotic pathway is initiated by the recruitment of FADD followed by the cleavage and activation of
caspase-8 (61). To examine whether vanadate-induced cell
death is mediated by the FADD-caspase-8 pathway, we used
DN-FADD and the caspase-8 inhibitor, Z-IETD-FMK, to block
the action of FADD and caspase-8, respectively. As shown in
Fig. 9, both DN-FADD and Z-IETD-FMK eliminated vanadateinduced cell death. Blockage of the activation of caspase-3 but
not caspase-9 also significantly inhibited vanadate-induced
apoptosis (Fig. 9B). These results support the notion that the
Fas-FADD-caspase-8 pathway plays a major role in vanadatetriggered cell death in CGPs.
To further investigate the role of JNK activation and ROS in

The present study demonstrates that vanadate at physiologically relevant concentrations (10 –100 M) inhibits the growth
of cultured CGPs. These concentrations, which range in micromoles, are comparable with the levels encountered in industrial settings (29). The CGPs proliferate in vitro, and vanadate
produces a marginal inhibition of the proliferation of CGPs. On
the other hand, vanadate dramatically increases the death of
CGPs. Therefore, vanadate-induced growth inhibition mainly
results from cell death. Vanadate-induced death of CGPs is
typical of apoptosis, which is verified by measuring various
apoptotic indices. Furthermore, the present study characterizes a signaling pathway that explains how vanadate exposure
induces neuronal apoptosis.
In general, the apoptotic signal can be transmitted through
either the death receptors, such as Fas, or mitochondria (63).
Fas (also called APO-1 or CD95) is a member of the tumor
necrosis receptor superfamily that transmits a death signal to
the cells (61). In Fas-mediated death, it is well known that the
binding to its ligand, FasL, or agonist antibodies induces aggregation of the receptor, which results in its interaction with
the death adapter molecule Fas-associated death domain
(FADD, also called MORT1) (63). FADD contains a death domain (DD) and a death effector domain (DED). On activation,
Fas associates with the death domain in FADD (61). Subsequently, procaspase-8 binds to the DED of FADD and forms a
death-inducing signal complex (DISC). on forming a DISC,
procaspase-8 is activated autoproteolytically and propagates
the apoptotic signal by activating executioner caspases such as
caspase-3 (63, 69, 70). Formation of the DISC could be FasLdependent or independent (51–74). In mitochondria-mediated
cell death, mitochondria sense the apoptotic signal and convey
it to the activation of adapter APAF-1 via the release of cytochrome c. Cytochrome c binds to APAF-1, and in the presence
of adenine nucleotides the APAF-1-cytochrome c complex promotes activation of procaspase-9 (75). Caspase-9 can activate
executioner caspases and trigger apoptosis (63).
Vanadate clearly triggers a death signal mediated by the
death receptor Fas. It up-regulates FasL expression, promotes
the Fas aggregation and the association of Fas with FADD, and
subsequently activates caspases (caspase-8 and -3). Apparently, vanadate-induced apoptosis occurs through this pathway
because blocking this pathway by either a DN-FADD or
caspase-8 inhibitor eliminates vanadate-induced cell death. In
Fas-mediated apoptosis, Fas is activated first by the binding to
its ligand (FasL) or agonist antibody (61). Our results show
that vanadate induces a robust increase of FasL expression.
Surprisingly, it appears that the FasL induction has a relatively minor contribution to vanadate-induced apoptosis. This
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FIG. 5. Measurement of vanadateinduced ROS generation by ESR. The
CGPs (1 ⫻ 106) were incubated in PBS
containing 100.0 mM DMPO and 1.0 mM
vanadate with or without different ROS
scavengers as indicated. ESR spectra
were recorded for 30 min. The final concentrations for ROS scavengers were: catalase, 2000 units/ml; superoxide dismutase, 5.0 g/ml; formate, 50.0 mM; and
deferoxamine, 2.0 mM.

FIG. 6. Effects of catalase, D-JNKI1,
and PD98059 on c-Jun and ERK activation. Cells were pretreated with catalase (2000 units/ml), PD98059 (50.0 M),
or D-JNKI1 (1.0 M) for 30 min before
vanadate treatment (25.0 M). A, c-Jun
activation. Cells were then exposed to
vanadate for 6 h, and c-Jun activation
was determined as described in the legend for Fig. 2. B, ERK activation. Cells
were then exposed to vanadate for 30 min,
and ERK activation was determined as
described in the legend for Fig. 2.

FIG. 7. Effects of ROS scavengers and inhibitors for MAPKs on vanadate-induced FasL production, Fas-FADD association, and
caspase-8 activation. Cells were pretreated with catalase (2000 units/ml), PD98059 (50.0 M), or D-JNKI1 (1.0 M) for 30 min before vanadate
treatment (25.0 M). A, FasL expression. Cells were exposed to vanadate for 24 h, and the expression of FasL was determined by immunoblot. B,
Fas-FADD association. Cells were then exposed to vanadate for 6 h, and Fas-FADD association was determined as described in Fig. 3. Panels on
the right were the microdensitometrical quantification of relative expression. C, caspase-8 activation. Cells were exposed to vanadate for 24 h, and
the activation of caspase-8 was determined as described under “Experimental Procedures.” The experiments were replicated three to four times.
*, statistically significant difference relative to control cultures (p ⬍ 0.05); #, statistically significant difference relative to vanadate-treated
cultures (p ⬍ 0.05); @, statistically significant difference relative to vanadate- and catalase-treated cultures (p ⬍ 0.05); &, statistically significant
difference relative to vanadate and JNKI-treated cultures (p ⬍ 0.05).
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FIG. 8. Effects of Fas antagonists on vanadate-mediated apoptosis. CGPs were exposed to vanadate for 24 h with or without
antibody SM1/23 (3.0 g/ml) or Fas-Fc fusion protein (40.0 M). Apoptosis was determined with a DNA fragmentation ELISA. The experiment was replicated four times. *, statistically significant difference
relative to control cultures (p ⬍ 0.05); #, statistically significant difference relative to vanadate-treated cultures (p ⬍ 0.05).

FIG. 9. Effects of dominant negative FADD (DN-FADD) and
caspase inhibitors on vanadate-mediated apoptosis. A, cells were
transfected with pEGFP-C3 and DN-FADD or empty pcDNA3.0 vector.
One day after transfection cells were exposed to vanadate (25.0 M) for
24 h, and apoptosis in the transfected cells was assayed by nuclei
fragmentation and condensation after TOTO-3 iodide staining as described under “Experimental Procedures.” Relative apoptosis in the
total transfected cells (green fluorescent protein-positive) was quantified. B, cells were pretreated with different caspase inhibitors for 30
min before vanadate exposure (25.0 M, 24 h). After vanadate treatment, apoptosis was determined with a DNA fragmentation ELISA.
The inhibitors for caspase-3 (Cas3-I), caspase-8 (Cas8-I), and caspase-9
(Cas9-I) were Ac-DMQD-CHO, Z-IETD-FMK, and ZlEHD-FMK, respectively. Each data point (bars; ⫾ S.E.) is the mean of three to four
independent trials. *, denotes a statistically significant difference relative to control group (p ⬍ 0.05). #, statistically significant difference
relative to vanadate-treated cultures (p ⬍ 0.05); @, statistically significant difference relative to vanadate and caspase 3-I-treated cultures
(p ⬍ 0.05).

argument is based on the observations that (a) the elimination
of vanadate-induced increase in FasL expression (by treatment
of catalase) does not inhibit Fas-FADD association, and only
produces a modest protection against vanadate-induced apoptosis, and (b) a blockage of FasL-Fas interaction by Fas antagonists has a marginal effect on vanadate-induced cell death.
Thus, it can be concluded that, although it participates, FasL
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FIG. 10. Effects of inhibitors for MAPKs and catalase on vanadate-induced apoptosis. Cells were pretreated with catalase (2000
units/ml), PD98059 (50.0 M), SB292190 (10.0 M), or D-JNKI1 (1.0 M)
for 30 min before vanadate treatment (25.0 M; 24 h). After vanadate
exposure, apoptosis was determined with a DNA fragmentation ELISA.
Each data point (bars; ⫾ S.E.) is the mean of four independent trials. *,
statistically significant difference relative to control cultures (p ⬍ 0.05);
@, statistically significant difference relative to vanadate-treated cultures (p ⬍ 0.05); #, statistically significant difference relative to vanadate- and catalase-treated cultures (p ⬍ 0.05); &, statistically significant difference relative to vanadate- and JNKI1-treated cultures
(p ⬍ 0.05).

induction is not the major contributor to vanadate-induced
apoptosis. This may be the result of the inefficiency in the level
of FasL induction to cause a substantial cell death. Therefore,
there must be other mechanisms independent of FasL induction that account for vanadate-induced death of CGPs.
Vanadate activates two MAPKs, ERK1/2 and JNK1, in
CGPs. The pattern of activation for each is different. The activation of ERKs is rapid and transient, whereas JNK activation
is relatively slow and more persistent (lasting for at least 12 h).
In addition, vanadate induces ROS generation in CGPs. It
appears that H2O2 is the major precursor of the 䡠OH radical
induced by vanadate because catalase (a specific H2O2 scavenger) eliminates the 䡠OH radical generated by vanadate. It
has been demonstrated that many effects of vanadate are mediated by its ability to generate ROS. For example, vanadateinduced activation of transcription factors such as NF-B, p53,
or hypoxia-inducible factor 1␣ (HIF-1␣) and the up-regulation
of tumor necrosis factor ␣ (TNF␣) expression are clearly mediated by ROS generation, particularly through the H2O2 accumulation (76 –79). Vanadate-induced JNK activation has been
observed in mouse macrophages, and the activation is also
dependent on ROS induction (76). However, the present study
demonstrates that the H2O2 scavenger catalase does not affect
the activation of JNK and ERKs, suggesting that ROS is not
involved in vanadate-induced activation of MAPKs in CGPs.
Vanadium compounds may serve as a PTP inhibitor that enhances protein tyrosine phosphorylation (59, 60). Our results
show that vanadate increases tyrosine phosphorylation on JNK1,
which suggests that vanadate-induced activation of signaling
proteins is mediated by its inhibition of PTPs. Thus, it appears
that the biological effect of vanadate is cell type-specific.
JNK activation can result in FasL expression in various cells
(22, 80 – 82). However, the present study shows that neither
JNK nor ERK activation is required for vanadate-induced increase in FasL production in CGPs. On the other hand, ROS
appears to be indispensable for vanadate-induced FasL production; the H2O2 scavenger catalase completely blocks vanadateinduced FasL expression. The exact signal pathway underlying
ROS regulation of FasL expression in CGPs remains to be
elucidated. Although JNK activation is not involved in FasL
induction, it is required for vanadate-induced Fas-FADD association. That is, vanadate-induced JNK activation initiates the
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Fas-FADD-caspase pathway in a FasL-independent manner.
This effect is mediated by FasL-independent Fas aggregation.
It has been reported that JNK activation triggers FasL-independent aggregation of Fas and subsequently evokes the
FADD-caspase pathway in Jurkat T cells (73). FasL-independent Fas aggregation has been observed on various stress stimuli, such as exposure to UV, cycloheximide, cisplatin, etoposide,
vinblastine, curcumin, and doxorubicin (83– 87).
Persistent activation of JNK is capable of triggering apoptotic pathways initiated by both the death receptor (such as
Fas) and mitochondria (88). Apoptosis of CGPs caused by vanadate-induced JNK activation is mediated primarily by the
death receptor Fas. This conclusion is supported by the following observations. First, vanadate-induced apoptosis is mediated by the FADD-caspase-8 pathway, and the blockage of JNK
activation abolishes Fas-FADD association and caspase-8 activation. Second, inhibition of JNK activation significantly reduces vanadate-mediated cell death. FasL induction has a modest but statistically significant contribution to vanadateinduced apoptosis. Simultaneously blocking JNK activation
and FasL expression totally abolishes vanadate-induced FasFADD association and the subsequent apoptosis. This result
indicates that both JNK activation and FasL induction contribute to vanadate-induced apoptosis, and JNKs are the major
contributors. Third, vanadate activates caspase-8 and -3 but
not caspase-9. Fas activation (Fas aggregation) results in the
formation of DISC that activates procaspase-8 (61). Activated
caspase-8 directly cleaves procaspase-3, an executioner
caspase, and triggers apoptosis (89). On the other hand, the
activation of caspase-9 is triggered mainly by damage to mitochondria and the release of cytochrome c. It is noted, however,
that cross-talk may exist between death receptor- and mitochondria-mediated cell death (90, 91).
In summary, JNK activation by vanadate initiates the FasFADD-caspase-8 signal pathway and triggers apoptosis in
CGPs. The finding that vanadate induces apoptosis in central
nervous system neurons may explain some of the central nervous system defects attributed to environmental exposure to
vanadate. The JNK and FADD-caspase-8 signal pathways may
also contribute to the neurotoxicity of other environmental
toxicants, such as heavy metals. Like vanadate, the heavy
metals, including arsenite, lead, lithium, and mercury, have
been shown to induce neuronal apoptosis (26, 71, 92–93). Understanding the role of JNK in apoptosis of neuronal precursors
will help elucidate the mechanisms of programmed cell death
in the developing nervous system.
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